The Clinical Stage Biotech Firms
We have reasons to believe that some clinical-stage biotechnology firms, which have yet to generate revenues, have solid scientific fundamentals, breakthrough technologies and extremely promising products that will generate billions of dollars in future years. These solid firms’ shareholders are currently experiencing selloffs of their stocks.
Short-sellers, and the followers who are encouraging the ridding of these stocks, explain that their pessimism is caused by the bad circumstances the whole world has been suffering through, those that started with the COVID-19 infection, followed by the loss of jobs, the extremely high price . . .